Dr. Hendrik Nogai is the Chief Medical Officer at Ryvu Therapeutics. Dr. Nogai is responsible for leading medical, clinical, and regulatory functions to support and guide the development of the company’s pipeline.
Hendrik Nogai is a board-certified medical doctor in Hematology/Oncology as well as in Internal Medicine, with almost 10 years of experience in patient care and basic research in different academic settings, including Charité – University Medicine Berlin, University Hospital in Munich, and Zentralklinikum Augsburg. Besides his clinical expertise, Dr. Nogai’s brings 17 years of industry experience including business consulting at Mercer Management Consulting/ Oliver Wyman, medical advisory at Nordic Biotech Capital ApS, and positions of increasing responsibility at Bayer AG, with his most recent role of Vice President, Global Development Leader NTRK program.
Dr. Nogai has completed his Medical Studies at Charité – University Medicine Berlin (Germany), Ludwig-Maximilians University in Munich (Germany) and Harvard Medical School in Boston (USA). He holds a doctoral degree awarded by the Humboldt University of Berlin (Germany) for his research on cell biology.
